Vitamin D, vitamin A, the primary melanoma transcriptome and survival.
Survival from melanoma is influenced by several, well-established clinical and histopathological factors, e.g. age, Breslow thickness and microscopic ulceration. We (the Section of Epidemiology and Biostatistics, University of Leeds) have carried out research to better understand the biological basis for these observations. Preliminary results indicated a protective role for vitamin D in melanoma relapse and that higher vitamin D was associated with thinner primary melanomas. Funding from the British Skin Foundation enabled JNB to establish a study of the effects of vitamin A in melanoma. The results suggested that vitamin A could reduce the protective effect of vitamin D in terms of overall survival. Therefore, we propose that vitamin D3supplementation alone might be preferable to combined multivitamin preparations, where vitamin D supplementation is deemed to be appropriate. Proving a causal link between vitamin D and melanoma-specific survival is challenging. We have shown limited evidence of causation in a Mendelian randomization experiment (described in more detail later). Recent work in Leeds has also shown that higher vitamin D may be protective for microscopic ulceration. Taken together, vitamin D appears to be associated with less aggressive primary melanomas and may itself influence outcome. We continue to explore the role of vitamin D in melanoma survival and the optimum levels that might be crucial.
Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Genetics Building, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
S J
SJ
O'Shea
Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Genetics Building, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
J R
JR
Davies
Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Genetics Building, St. James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. j.a.newton-bishop@leeds.ac.uk.
J A
JA
Newton-Bishop
Int J Cancer. 2015 Jun 15;136(12 ):2890-9
25403087
Am J Clin Nutr. 2009 May;89(5):1321-7
19321573
Cancer Causes Control. 2011 Oct;22(10 ):1471-82
21853245
J Clin Oncol. 2013 Jun 20;31(18):2337-46
23690423
Br J Dermatol. 2013 Mar;168(3):625-8
22880705
N Engl J Med. 2014 Feb 13;370(7):599-609
24521106
J Nutr. 1999 Dec;129(12):2246-50
10573558
Br J Cancer. 2010 Oct 12;103(8):1229-36
20859289
Clin Nutr. 2013 Dec;32(6):1012-6
23669635
Arch Intern Med. 2007 Sep 10;167(16):1730-7
17846391
Cancer Prev Res (Phila). 2014 Feb;7(2):218-25
24327720
Nat Rev Cancer. 2007 Sep;7(9):684-700
17721433
Front Biosci. 2005 Sep 01;10:2723-49
15970529
Pigment Cell Melanoma Res. 2014 Mar;27(2):234-43
24219834
J Clin Oncol. 2009 Nov 10;27(32):5439-44
19770375
Hum Mol Genet. 2010 Jul 1;19(13):2739-45
20418485
Mod Pathol. 2012 Apr;25(4):493-504
22080065
Anticancer Res. 2006 Jul-Aug;26(4A):2701-5
16886680
Oncotarget. 2015 May 10;6(13):11683-93
25871393
Curr Opin Oncol. 2012 Mar;24(2):137-40
22234255
J Clin Oncol. 2009 Dec 20;27(36):6199-206
19917835
Clin Cancer Res. 2015 Feb 15;21(4):844-53
25501129
Pigment Cell Melanoma Res. 2015 Jan;28(1):94-104
25220403
Lancet. 2010 Jul 17;376(9736):180-8
20541252
J Clin Oncol. 2016 May 20;34(15):1741-7
27001565
Am J Cardiol. 2012 Jan 15;109(2):226-30
21996139